FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
AJMC,
This article was originally published by NeurologyLive. The FDA has allowed Tiziana Life Sciences’ agent foralumab, a fully…
This article was originally published by NeurologyLive. The FDA has allowed Tiziana Life Sciences’ agent foralumab, a fully…
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve…
FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease Aug 15, 2023 Isabella Ciccone, MPH Foralumab, a therapy…
Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active…